Stravitz R Todd, Kramer Andreas H, Davern Timothy, Shaikh A Obaid S, Caldwell Stephen H, Mehta Ravindra L, Blei Andres T, Fontana Robert J, McGuire Brendan M, Rossaro Lorenzo, Smith Alastair D, Lee William M
Section of Hepatology, Virginia Commonwealth University, Richmond, USA.
Crit Care Med. 2007 Nov;35(11):2498-508. doi: 10.1097/01.CCM.0000287592.94554.5F.
To provide a uniform platform from which to study acute liver failure, the U.S. Acute Liver Failure Study Group has sought to standardize the management of patients with acute liver failure within participating centers.
In areas where consensus could not be reached because of divergent practices and a paucity of studies in acute liver failure patients, additional information was gleaned from the intensive care literature and literature on the management of intracranial hypertension in non-acute liver failure patients. Experts in diverse fields were included in the development of a standard study-wide management protocol.
Intracranial pressure monitoring is recommended in patients with advanced hepatic encephalopathy who are awaiting orthotopic liver transplantation. At an intracranial pressure of > or =25 mm Hg, osmotic therapy should be instituted with intravenous mannitol boluses. Patients with acute liver failure should be maintained in a mildly hyperosmotic state to minimize cerebral edema. Accordingly, serum sodium should be maintained at least within high normal limits, but hypertonic saline administered to 145-155 mmol/L may be considered in patients with intracranial hypertension refractory to mannitol. Data are insufficient to recommend further therapy in patients who fail osmotherapy, although the induction of moderate hypothermia appears to be promising as a bridge to orthotopic liver transplantation. Empirical broad-spectrum antibiotics should be administered to any patient with acute liver failure who develops signs of the systemic inflammatory response syndrome, or unexplained progression to higher grades of encephalopathy. Other recommendations encompassing specific hematologic, renal, pulmonary, and endocrine complications of acute liver failure patients are provided, including their management during and after orthotopic liver transplantation.
The present consensus details the intensive care management of patients with acute liver failure. Such guidelines may be useful not only for the management of individual patients with acute liver failure, but also to improve the uniformity of practices across academic centers for the purpose of collaborative studies.
为研究急性肝衰竭提供一个统一的平台,美国急性肝衰竭研究小组试图在参与研究的各中心规范急性肝衰竭患者的管理。
由于急性肝衰竭患者的治疗方法存在差异且相关研究较少,在无法达成共识的领域,从重症监护文献以及非急性肝衰竭患者颅内高压管理的文献中收集了更多信息。不同领域的专家参与了标准的全研究范围管理方案的制定。
对于等待原位肝移植的晚期肝性脑病患者,建议进行颅内压监测。当颅内压≥25mmHg时,应静脉推注甘露醇进行渗透性治疗。急性肝衰竭患者应维持轻度高渗状态以尽量减少脑水肿。因此,血清钠应至少维持在高正常范围内,但对于甘露醇治疗无效的颅内高压患者,可考虑给予高渗盐水使血清钠达到145 - 155mmol/L。对于渗透性治疗失败的患者,虽然诱导适度低温作为原位肝移植的过渡治疗似乎很有前景,但目前数据不足以推荐进一步治疗。对于任何出现全身炎症反应综合征体征或原因不明的肝性脑病进展至更高等级的急性肝衰竭患者,应给予经验性广谱抗生素治疗。还提供了针对急性肝衰竭患者特定血液学、肾脏、肺部和内分泌并发症的其他建议,包括原位肝移植期间及之后的管理。
本共识详细阐述了急性肝衰竭患者的重症监护管理。此类指南不仅可能有助于急性肝衰竭个体患者的管理,还可提高各学术中心实践的一致性,以利于开展协作研究。